Advagene Biopharma Co., Ltd. (6709.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$24.10 (+0.42%) as of
Key statistics
- Market cap
- 1.67B
- EPS (TTM)
- -1.51
- Dividend yield
- 0.00%
- 52-week range
- 22.50 – 36.20
- Beta
- 0.68
- Profit margin
- 0.00%
- Volume
- 33.88k
About Advagene Biopharma Co., Ltd.
Advagene Biopharma Co., Ltd. engages in the research and development of vaccine technology and related products in Taiwan. The company engages in the development of nasal spray influenza and COVID-19 vaccine; respiratory allergy treatment vaccine, including rhinitis and athsma; and other vaccines. Advagene Biopharma Co., Ltd. was founded in 2006 and is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Taipei, Taiwan
- Employees
- 16
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.